INDUSTRY

NEW YORK -- IMPATH Inc. announced that its Board of Directors has appointed Carter H. Eckert as Chairman and Chief Executive Officer, effective immediately, to replace Anu D. Saad, Ph.D., who has resigned following a review of expenses submitted by Dr. Saad over the last three years. Following this review, which was led by IMPATH's Audit Committee, Dr. Saad and the Board agreed the resignation was in the best interests of the Company, and she has agreed to reimburse the Company in the amount of $250,000. The Company said that the review would not result in any restatement of the results for any prior period and reaffirms its commitment to corporate integrity at all levels. Dr. Saad was appointed CEO in 1993 and became Chairman in 2001. She has made valuable contributions during her 13 years with IMPATH and will continue as a consultant to the Company to assist in the management transition. The Company is extremely pleased to welcome Carter to the management team. Mr. Eckert has been a Board member since April 2002 and has extensive experience in the healthcare industry. Mr. Eckert said, "Since joining the Board nearly a year ago, I have been very impressed with IMPATH's business model and strongly believe that the full potential of the business is unrealized. I am looking forward to working with our President Rich Adelson and the rest of the management team in helping us reach the next level and in facilitating a seamless transition." Mr. Eckert currently serves on the Board of Directors of OraSure Technologies, Inc. and is a member of the Aethena Group, LLC advisory board. He is a Trustee of Caldwell College and the Morristown Memorial Health Foundation. Mr. Eckert also served on the Board of Directors of Boron, Lepore & Associates, Inc. until it was acquired by Cardinal Health, Inc. in June of 2002. Mr. Eckert received his B.S. in Chemical Engineering from the Illinois Institute of Technology and his MBA from Northwestern University. Mr. Eckert's prior experience includes serving as President and Chief Executive Officer of Knoll Pharmaceutical Company and President of the Americas for Knoll's parent company, BASF Pharma. In addition, he was a member of BASF Pharma's Global Pharmaceutical Board, responsible for global therapeutic franchises and corporate transactions. Prior to joining BASF Pharma in 1995, Mr. Eckert was President and Chief Executive Officer of Boots Pharmaceuticals, Inc. in Lincolnshire, IL, where he was responsible for North American operations. Eckert joined Boots in 1985 as Executive Vice President and Chief Operating Officer after more than a decade at Baxter Travenol Laboratories in Deerfield, IL, where he served in a number of positions including President of Baxter's Pharmaceutical Division.